Neuroscience

Dr. Robert Melillo and ‘A Moment of Xen’ join forces to bring ‘Brain-Based Wellness’ to National Radio, Digital Streaming TV, and social platforms

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- 'A Moment of Xen', the acclaimed Tri-State talk show hosted by celebrated media...

Abridge Partnership Scales Ambient Clinical Intelligence Across Hartford HealthCare’s Clinical Enterprise

HARTFORD, Conn. & PITTSBURGH--(BUSINESS WIRE)--Abridge’s AI-powered ambient clinical intelligence platform has been selected by Hartford HealthCare, Connecticut’s most comprehensive healthcare...

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in...

Pathway to Cures Portfolio Company Spark Biomedical Receives Wellcome Leap Award for Advancements in Women’s Health: Heavy Menstrual Bleeding

NEW YORK--(BUSINESS WIRE)--#NBDF--Pathway to Cures (P2C) congratulates Dr. Navid Khodaparast, PhD, co-founder and CSO of P2C portfolio company Spark Biomedical,...

Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease

Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE)...

Landmark Medical Study Reveals Patented Immersive Audio Solution’s Breakthrough Impact on AR/VR Applications Across Multiple Industries

Digital Power Station's suite of Immersive Audio Solutions Drives Transformative Advances in Healthcare, Therapy, Education, and Entertainment PORT ST. LUCIE,...

Skyhawk Therapeutics Announces Strategic Collaboration with Merck KGaA, Darmstadt, Germany to Discover Novel RNA-Targeting Small Molecules for Neurological Disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued...

Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)

-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)...

error: Content is protected !!